Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Aug 30, 2024

SELL
$6.81 - $39.55 $2,655 - $15,424
-390 Closed
0 $0
Q4 2018

Aug 30, 2024

BUY
$9.15 - $12.26 $3,568 - $4,781
390 New
390 $4.26 Million
Q1 2017

Aug 30, 2024

BUY
N/A
390
390 $2.84 Million

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.